SCHEMBL4745857

SCHEMBL4745857

CC(C)(C)c1ccc2c(-c3cc4c5cccc6c5c(cc4c4ccccc34)-c3ncccc3-6)cc(C(C)(C)C)cc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.38
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
NPC1 O15118 1/20 0.33
PLA2G1B P04054 1/20 0.33
NFKB1 P19838 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
KIF11 P52732 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745946 0.86 CYP1A2 (0.35) KDRALDH1A1L3MBTL1HPGDTSHR
SCHEMBL4745833 0.82 KDR (0.34) KDRALDH1A1L3MBTL1NPC1PLA2G1B
SCHEMBL4745800 0.82 ALDH1A1 (0.36) KDRALDH1A1KMT2AKDM4EKIF11
SCHEMBL4745828 0.81 KDR (0.36) KDRALDH1A1KMT2AKDM4EKIF11
SCHEMBL4746454 0.81 ALDH1A1 (0.40) ALDH1A1L3MBTL1KMT2AKDM4EHPGD
SCHEMBL4746267 0.81 ALDH1A1 (0.42) ALDH1A1L3MBTL1KMT2AKDM4EHPGD
SCHEMBL4745831 0.80
SCHEMBL4745841 0.80 ALDH1A1 (0.44) ALDH1A1L3MBTL1NPC1KMT2AKDM4E
SCHEMBL4746392 0.80 ALDH1A1 (0.41) ALDH1A1L3MBTL1KMT2AKDM4EHPGD
SCHEMBL4745930 0.79 ALDH1A1 (0.46) ALDH1A1L3MBTL1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 KDR 944/4885ALDH1A1 179/4885L3MBTL1 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.